Karyopharm Therapeutics (KPTI) Enterprise Value (2013 - 2026)

Karyopharm Therapeutics (KPTI) has reported Enterprise Value for 14 consecutive years, with $217.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 1608.27% year-over-year to $217.6 million; the trailing twelve-month figure through Jun 2026 stood at $217.6 million (up 1608.27% YoY), and the FY2025 full-year result was $16.7 million, up 128.26% from the prior year.
• Enterprise Value advanced to $217.6 million in Q2 2026 per KPTI's latest filing, from $16.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at $380.0 million in Q1 2022 and bottomed at -$92.0 million in Q4 2023.
• Historically, Enterprise Value has averaged $55.3 million across 5 years, with a median of $408340.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Enterprise Value tumbled 22629.82% in 2023, then jumped 1608.27% in 2026.
• Over 5 years, Enterprise Value stood at $408340.0 in 2022, then sank by 22629.82% to -$92.0 million in 2023, then jumped by 35.63% to -$59.2 million in 2024, then jumped by 128.26% to $16.7 million in 2025, then jumped by 1200.18% to $217.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $217.6 million, $16.7 million, and $11.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.